Poolbeg Pharma (LON:POLB) Stock Price Down 4.3% – Should You Sell?

Shares of Poolbeg Pharma PLC (LON:POLB) fell 4.3% during trading on Wednesday . The company traded as low as GBX 4.50 and last traded at GBX 4.50. 125,518 shares changed hands during trading, a decline of 93% from the average session volume of 1,811,560 shares. The stock had previously closed at GBX 4.70.

Analysts Set New Price Targets

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Wednesday, January 28th.

Poolbeg Pharma Stock Up 1.2%

The stock has a 50 day moving average of GBX 4.33 and a 200 day moving average of GBX 3.85. The company has a market capitalization of £33.55 million, a price-to-earnings ratio of -4.17 and a beta of 2.11.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.